Back to top

Analyst Blog

Zacks Equity Research

Intuitive Surgical: A Strong Buy

ISRG MYGN

 ZacksTrade Now

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Rising earnings estimates on the back of strong third quarter results - including a 28.2% earnings surprise - helped Intuitive Surgical (ISRG - Analyst Report) achieve a Zacks #1 Rank (Strong Buy) on January 1, 2013. Moreover, this pioneer of robotic surgery has delivered a positive earnings surprise in each of the last five quarters with an average beat of 13.7%.

The Rank Driver

We expect a number of procedures that are currently completed either in an open surgical manner or with laparoscopy to be eventually replaced by da Vinci surgery, as robotic surgery becomes the standard of care in many instances. The company enjoys a virtual monopoly in robotic surgery with little competition.

Intuitive’s recurring revenue stream continues to be robust and provides a shield against cyclicality of revenues arising from the sale of discretionary capital equipment to hospitals. Recurring revenues continue to grow as a proportion of total sales. It increased 24% year over year in the third quarter and constituted 57% of revenues.

However, we believe that until the global economy fully recovers, the stock may come under periodic pressure as investors ponder whether lingering macro economic uncertainty weakens hospitals’ commitment towards investment in high-cost robotic systems. In the interim, the installed base of Intuitive continues to grow as hospitals are compelled to upgrade their systems.

Overall, a reasonable valuation is appropriate given positive factors such as Intuitive’s leading position in robotic surgery, a growing list of emerging procedures, barriers to entry, sizeable cash and no debt.

The company tweaked its guidance for revenues and operating income for 2012 along with its third quarter results. For 2012, revenues are forecast to grow in the range of 21.5% to 23% compared with the earlier guidance of 20% to 23%. Operating income is expected at about 40% compared to approximately 39% to 40% of net sales earlier. The company lowered its procedure growth at 24% (earlier in the band of 25% and 27%) for 2012.

Earnings Estimate Revisions

The Zacks Consensus Estimate for 2012 increased 0.3% to $14.85 per share based on 6 out of 8 upward estimate revisions over the last 60 days. The current estimate implies year-over-year growth of 20.6%.

Valuation

Intuitive currently trades at a forward P/E of 33.4x, a 77.8% premium to the peer group average of 18.8x. Also, on a price-to-book basis, the shares are trading at 6.0x, a 42.9% premium to the peer group average of 4.2x. Given the company’s strong fundamentals, the premium valuation is justified.

Intuitive has a trailing 12-month ROE of 18% compared with the peer group average of 12.3%.

About the Company

Headquartered in Sunnyvale, California, Intuitive specializes in minimally invasive robotic surgery. Its systems find application in gynecology and prostatectomy procedures besides a host of emerging procedures. The company has a market capitalization of about $19.5 billion.

Other Zacks #1 Rank (Strong Buy) stocks include Myriad Genetics Inc. (MYGN - Analyst Report) and Cantel Medical Corp. .

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GRP IN DXYN 15.84 +7.90%
BOFI HLDG IN BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%